Serum Periostin Is Associated With Fracture Risk in Postmenopausal Women: A 7-Year Prospective Analysis of the OFELY Study
Purpose:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture ris...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 99; no. 7; pp. 2533 - 2539 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
01.07.2014
Copyright by The Endocrine Society |
Subjects | |
Online Access | Get full text |
ISSN | 0021-972X 1945-7197 1945-7197 |
DOI | 10.1210/jc.2013-3893 |
Cover
Loading…
Abstract | Purpose:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown.Subjects and Methods:Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured.Results:At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1–3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < −2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4–21.8) after adjustment for age.Conclusion:High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment. |
---|---|
AbstractList | Purpose:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown.Subjects and Methods:Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured.Results:At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1–3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < −2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4–21.8) after adjustment for age.Conclusion:High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment. PURPOSE:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown. SUBJECTS AND METHODS:Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured. RESULTS:At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1–3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < −2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4–21.8) after adjustment for age. CONCLUSION:High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment. Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown.PURPOSEPeriostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown.Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured.SUBJECTS AND METHODSSerum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured.At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1-3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < -2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4-21.8) after adjustment for age.RESULTSAt baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1-3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < -2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4-21.8) after adjustment for age.High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment.CONCLUSIONHigh serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment. Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown. Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured. At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1-3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < -2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4-21.8) after adjustment for age. High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment. |
Author | Chapurlat, R. Garnero, P. Sornay-Rendu, E. Rousseau, J. C. Bertholon, C. |
AuthorAffiliation | INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), Université de Lyon, and Service de Rhumatologie et Pathologie Osseuse (R.C.), Hôpital E.-Herriot, Université de Lyon, 69437 Lyon Cedex 03, France; and Cisbio Bioassays (P.G.), 30200 Codolet, France |
AuthorAffiliation_xml | – name: INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), Université de Lyon, and Service de Rhumatologie et Pathologie Osseuse (R.C.), Hôpital E.-Herriot, Université de Lyon, 69437 Lyon Cedex 03, France; and Cisbio Bioassays (P.G.), 30200 Codolet, France |
Author_xml | – sequence: 1 givenname: J. C. surname: Rousseau fullname: Rousseau, J. C. email: jean-charles.rousseau@inserm.fr organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France – sequence: 2 givenname: E. surname: Sornay-Rendu fullname: Sornay-Rendu, E. organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France – sequence: 3 givenname: C. surname: Bertholon fullname: Bertholon, C. organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France – sequence: 4 givenname: R. surname: Chapurlat fullname: Chapurlat, R. organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France – sequence: 5 givenname: P. surname: Garnero fullname: Garnero, P. organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24628551$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1rGzEQxUVJaZy0t56LoIf20E31uavtzYQ4DRhimpY0J6HIs1jOerXVR4P710euk0sgAjEM_N4Mek9H6GDwAyD0npITyij5urYnjFBecdXyV2hCWyGrhrbNAZoQwmjVNuz3ITqKcU0IFULyN-iQiZopKekE_buCkDd4AcH5mNyALyKexuitMwmW-NqlFZ4FY1MOgH-4eIcLsyjoBgY_mhxNj699ab7hKW6qGzABL4KPI9jk_gKeDqbfRhex73BaAb6cnc1v8FXKy-1b9LozfYR3j_UY_Zqd_Tz9Xs0vzy9Op_PK8rYmlQGyhJY3RhkqFe06sJRBJwgQo0TH20Z0shTZKCMVobK1TW1UTaUkXNFbfow-7-eOwf_JEJPeuGih780APkdNpRCc0ZbIgn58hq59DuUJUXNaF_NUzVmhPjxS-XYDSz0GtzFhq59cLQDbA7Y4EQN02rpkkvNDCsb1mhK9i06vrd5Fp3fRFdGXZ6KnuS_gYo_f-z5BiHd9voegV2D6tNKkHFE3qioCQZrSVeVyUmSf9jKfx5cW_P9K_AEvy7My |
CitedBy_id | crossref_primary_10_1002_mus_26195 crossref_primary_10_1016_j_bone_2019_07_019 crossref_primary_10_1007_s00774_020_01200_3 crossref_primary_10_1111_jcpe_12432 crossref_primary_10_1007_s11914_020_00601_7 crossref_primary_10_1016_j_bone_2015_08_014 crossref_primary_10_3389_fmed_2023_1276900 crossref_primary_10_1007_s12020_015_0803_7 crossref_primary_10_1055_a_2053_8090 crossref_primary_10_1161_CIRCGEN_120_003258 crossref_primary_10_1007_s10238_018_0532_3 crossref_primary_10_1016_j_hrtlng_2020_04_017 crossref_primary_10_3390_cancers15235562 crossref_primary_10_1016_j_jbspin_2015_01_023 crossref_primary_10_1007_s00198_015_3442_1 crossref_primary_10_1016_j_rhum_2016_08_009 crossref_primary_10_1007_s00508_018_1386_0 crossref_primary_10_1016_j_bone_2014_05_016 crossref_primary_10_1093_rheumatology_kev410 crossref_primary_10_3803_EnM_2016_31_3_400 crossref_primary_10_1038_bcj_2016_90 crossref_primary_10_1097_MCO_0000000000000210 crossref_primary_10_1007_s00198_016_3839_5 crossref_primary_10_1016_j_bone_2017_03_041 crossref_primary_10_1016_j_metabol_2017_03_017 crossref_primary_10_1002_jbmr_3203 crossref_primary_10_3390_genes13030439 crossref_primary_10_1007_s12018_015_9185_x crossref_primary_10_1111_odi_13664 crossref_primary_10_1007_s13277_015_3386_2 crossref_primary_10_3390_ijms25179159 crossref_primary_10_2147_IJGM_S335296 crossref_primary_10_1016_j_bone_2019_04_023 crossref_primary_10_1007_s00198_017_4272_0 crossref_primary_10_3803_EnM_2016_31_3_454 crossref_primary_10_1007_s40618_017_0820_x crossref_primary_10_1007_s40291_017_0272_1 crossref_primary_10_1016_j_cca_2018_03_009 crossref_primary_10_1007_s10549_020_05570_0 crossref_primary_10_1016_j_bone_2019_01_004 crossref_primary_10_1210_jc_2017_00283 crossref_primary_10_1080_09603123_2022_2163989 crossref_primary_10_1016_j_joca_2015_05_015 crossref_primary_10_1007_s00198_017_4034_z crossref_primary_10_1007_s00223_017_0302_3 crossref_primary_10_3390_nu16050605 crossref_primary_10_1080_17474086_2017_1283213 crossref_primary_10_3390_biomedicines11020603 crossref_primary_10_3803_EnM_2020_35_1_55 crossref_primary_10_1007_s00198_021_06018_x crossref_primary_10_1530_EC_18_0186 crossref_primary_10_1210_clinem_dgz259 crossref_primary_10_1021_acs_jproteome_8b00637 crossref_primary_10_1007_s00223_018_0444_y crossref_primary_10_1007_s12020_015_0735_2 crossref_primary_10_1093_nutrit_nuab061 |
Cites_doi | 10.1007/s00223-012-9642-1 10.1016/j.bone.2004.09.004 10.1016/j.humpath.2008.07.008 10.1359/jbmr.2002.17.5.826 10.1172/JCI40973 10.1128/MCB.24.9.3992-4003.2004 10.1161/01.ATV.0000149141.81230.c6 10.1074/jbc.M109.060335 10.1128/MCB.25.24.11131-11144.2005 10.1016/S8756-3282(00)00325-2 10.3109/07435800.2013.794425 10.1002/ijc.25591 10.1007/s00441-007-0439-x 10.1023/A:1021899904332 10.1007/s00198-011-1861-1 10.1007/s001980200068 10.1359/jbmr.2000.15.8.1526 10.1369/jhc.7A7321.2007 10.1074/jbc.M708029200 10.1002/dvdy.10453 10.1359/jbmr.1999.14.7.1239 10.1371/journal.pone.0031974 10.1073/pnas.1203085109 10.1007/s00198-011-1892-7 10.1007/s00198-010-1501-1 10.1210/jc.2003-030964 10.1359/JBMR.050609 10.1002/jbmr.5650110307 10.1093/ndt/gfr670 10.1359/jbmr.1997.12.4.683 10.1016/j.jbspin.2011.05.004 10.1359/jbmr.090831 10.1016/S0925-4773(01)00356-2 10.1016/S0272-6386(03)00905-3 10.1002/jbmr.5650080915 |
ContentType | Journal Article |
Copyright | Copyright © 2014 by the Endocrine Society 2014 Copyright © 2014 by The Endocrine Society Copyright © 2014 by the Endocrine Society |
Copyright_xml | – notice: Copyright © 2014 by the Endocrine Society 2014 – notice: Copyright © 2014 by The Endocrine Society – notice: Copyright © 2014 by the Endocrine Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 |
DOI | 10.1210/jc.2013-3893 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-7197 |
EndPage | 2539 |
ExternalDocumentID | 24628551 10_1210_jc_2013_3893 00004678-201407000-00030 10.1210/jc.2013-3893 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | France |
GeographicLocations_xml | – name: France |
GroupedDBID | --- -~X .55 .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 4.4 48X 53G 5GY 5RS 5YH 8F7 AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABBLC ABDFA ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ACGFO ACGFS ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK AELWJ AEMDU AENEX AENZO AETBJ AEWNT AFCHL AFFZL AFGWE AFOFC AFRAH AFXAL AGINJ AGKRT AGQXC AGUTN AHMBA AHMMS AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BSWAC BTRTY C45 CDBKE CS3 D-I DAKXR DIK E3Z EBS EJD EMOBN ENERS F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 HZ~ H~9 KBUDW KOP KQ8 KSI KSN L7B M5~ MHKGH MJL N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G REU ROX ROZ TEORI TJX TLC TR2 TWZ VVN W8F WOQ X7M YBU YFH YHG YOC YSK ZY1 ~02 ~H1 .GJ 3O- 7X7 88E 8FI 8FJ AAJQQ AAKAS AAPGJ AAQQT AAUQX AAWDT AAYJJ ABDPE ABUWG ABXZS ACFRR ACVCV ACZBC ADMTO ADNBA ADZCM AEMQT AEOTA AERZD AFFNX AFFQV AFKRA AFYAG AGMDO AGORE AHGBF AI. AJBYB AJDVS ALXQX APJGH AQDSO AQKUS AVNTJ BENPR BPHCQ BVXVI CCPQU EIHJH FEDTE FYUFA HMCUK HVGLF IAO IHR INH ITC J5H M1P MBLQV N4W NU- OBFPC PHGZM PHGZT PQQKQ PROAC PSQYO TMA UKHRP VH1 WHG X52 ZGI ZXP AAYXX CITATION CGR CUY CVF ECM EIF NPM PJZUB PPXIY 7QP 7T5 7TM H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3960-ae0de937a8a1581ffec12ef40e0a84f3974f5f39578a580159c76a861550381b3 |
ISSN | 0021-972X 1945-7197 |
IngestDate | Fri Jul 11 02:32:22 EDT 2025 Mon Jun 30 12:42:22 EDT 2025 Mon Jul 21 06:07:24 EDT 2025 Thu Apr 24 22:56:44 EDT 2025 Tue Jul 01 01:10:30 EDT 2025 Fri May 16 03:44:11 EDT 2025 Fri Feb 07 10:35:44 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3960-ae0de937a8a1581ffec12ef40e0a84f3974f5f39578a580159c76a861550381b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 24628551 |
PQID | 3164458632 |
PQPubID | 2046206 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1544321905 proquest_journals_3164458632 pubmed_primary_24628551 crossref_citationtrail_10_1210_jc_2013_3893 crossref_primary_10_1210_jc_2013_3893 wolterskluwer_health_00004678-201407000-00030 oup_primary_10_1210_jc_2013-3893 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-July |
PublicationDateYYYYMMDD | 2014-07-01 |
PublicationDate_xml | – month: 07 year: 2014 text: 2014-July |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Washington |
PublicationTitle | The journal of clinical endocrinology and metabolism |
PublicationTitleAlternate | J Clin Endocrinol Metab |
PublicationYear | 2014 |
Publisher | Oxford University Press Copyright by The Endocrine Society |
Publisher_xml | – name: Oxford University Press – name: Copyright by The Endocrine Society |
References | Simon ( key 2019041114010700100_B35) 2014; 39 Xiao ( key 2019041114010700100_B18) 2012; 23 National Kidney Foundation ( key 2019041114010700100_B22) 2003; 42 Chopin ( key 2019041114010700100_B7) 2012; 79 Kruzynska-Frejtag ( key 2019041114010700100_B15) 2001; 103 Sasaki ( key 2019041114010700100_B27) 2003; 77 Merle ( key 2019041114010700100_B10) 2012; 23 Bonnet ( key 2019041114010700100_B17) 2012; 109 Satirapoj ( key 2019041114010700100_B32) 2012; 27 Sornay-Rendu ( key 2019041114010700100_B2) 2005; 20 Rios ( key 2019041114010700100_B25) 2005; 25 Szulc ( key 2019041114010700100_B24) 2005; 36 Genant ( key 2019041114010700100_B23) 1993; 8 Bacchetta ( key 2019041114010700100_B31) 2010; 25 Contie ( key 2019041114010700100_B19) 2011; 128 Johnell ( key 2019041114010700100_B5) 2002; 13 Horiuchi ( key 2019041114010700100_B13) 1999; 14 Arlot ( key 2019041114010700100_B20) 1997; 12 Gillan ( key 2019041114010700100_B28) 2002; 62 Garnero ( key 2019041114010700100_B1) 2004; 4 Vasikaran ( key 2019041114010700100_B3) 2011; 22 Yoshiba ( key 2019041114010700100_B26) 2007; 330 Chapurlat ( key 2019041114010700100_B6) 2000; 27 Kruzynska-Frejtag ( key 2019041114010700100_B14) 2004; 229 Kim ( key 2019041114010700100_B36) 2012; 91 Coutu ( key 2019041114010700100_B9) 2008; 283 Lindner ( key 2019041114010700100_B30) 2005; 25 Shao ( key 2019041114010700100_B29) 2004; 24 Schulz ( key 2019041114010700100_B37) 2004; 89 Garnero ( key 2019041114010700100_B8) 2002; 17 Guerrot ( key 2019041114010700100_B33) 2012; 7 Hakuno ( key 2019041114010700100_B34) 2010; 120 Bonnet ( key 2019041114010700100_B16) 2009; 284 Garnero ( key 2019041114010700100_B4) 2000; 15 Zhu ( key 2019041114010700100_B12) 2008; 56 Garnero ( key 2019041114010700100_B21) 1996; 11 Kashima ( key 2019041114010700100_B11) 2009; 40 |
References_xml | – volume: 91 start-page: 370 year: 2012 ident: key 2019041114010700100_B36 article-title: Aortic calcification and bone metabolism: the relationship between aortic calcification, BMD, vertebral fracture, 25-hydroxyvitamin D, and osteocalcin publication-title: Calcif Tissue Int doi: 10.1007/s00223-012-9642-1 – volume: 36 start-page: 13 year: 2005 ident: key 2019041114010700100_B24 article-title: Biochemical markers of bone formation reflect endosteal bone loss in elderly men—MINOS study publication-title: Bone doi: 10.1016/j.bone.2004.09.004 – volume: 40 start-page: 226 year: 2009 ident: key 2019041114010700100_B11 article-title: Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions publication-title: Hum Pathol doi: 10.1016/j.humpath.2008.07.008 – volume: 17 start-page: 826 year: 2002 ident: key 2019041114010700100_B8 article-title: Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study publication-title: J Bone Miner Res doi: 10.1359/jbmr.2002.17.5.826 – volume: 4 start-page: 50 year: 2004 ident: key 2019041114010700100_B1 article-title: Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women publication-title: J Musculoskelet Neuronal Interact – volume: 120 start-page: 2292 year: 2010 ident: key 2019041114010700100_B34 article-title: Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents publication-title: J Clin Invest doi: 10.1172/JCI40973 – volume: 24 start-page: 3992 year: 2004 ident: key 2019041114010700100_B29 article-title: Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression publication-title: Mol Cell Biol doi: 10.1128/MCB.24.9.3992-4003.2004 – volume: 25 start-page: 77 year: 2005 ident: key 2019041114010700100_B30 article-title: Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000149141.81230.c6 – volume: 284 start-page: 35939 year: 2009 ident: key 2019041114010700100_B16 article-title: The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity publication-title: J Biol Chem doi: 10.1074/jbc.M109.060335 – volume: 25 start-page: 11131 year: 2005 ident: key 2019041114010700100_B25 article-title: Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype publication-title: Mol Cell Biol doi: 10.1128/MCB.25.24.11131-11144.2005 – volume: 27 start-page: 283 year: 2000 ident: key 2019041114010700100_B6 article-title: Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study publication-title: Bone doi: 10.1016/S8756-3282(00)00325-2 – volume: 39 start-page: 1 issue: 1 year: 2014 ident: key 2019041114010700100_B35 article-title: Bone mineral density, vertebral fractures and body mass index in postmenopausal women with abdominal aortic calcification publication-title: Endocr Res doi: 10.3109/07435800.2013.794425 – volume: 128 start-page: 352 year: 2011 ident: key 2019041114010700100_B19 article-title: Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases publication-title: Int J Cancer doi: 10.1002/ijc.25591 – volume: 62 start-page: 5358 year: 2002 ident: key 2019041114010700100_B28 article-title: Periostin secreted by epithelial ovarian carcinoma is a ligand for α(V)β(3) and α(V)β(5) integrins and promotes cell motility publication-title: Cancer Res – volume: 330 start-page: 133 year: 2007 ident: key 2019041114010700100_B26 article-title: Association of TIMP-2 with extracellular matrix exposed to mechanical stress and its co-distribution with periostin during mouse mandible development publication-title: Cell Tissue Res doi: 10.1007/s00441-007-0439-x – volume: 77 start-page: 245 year: 2003 ident: key 2019041114010700100_B27 article-title: Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer publication-title: Breast Cancer Res Treat doi: 10.1023/A:1021899904332 – volume: 23 start-page: 1877 year: 2012 ident: key 2019041114010700100_B18 article-title: Association of CDX1 binding site of periostin gene with bone mineral density and vertebral fracture risk publication-title: Osteoporos Int doi: 10.1007/s00198-011-1861-1 – volume: 13 start-page: 523 year: 2002 ident: key 2019041114010700100_B5 article-title: Biochemical indices of bone turnover and the assessment of fracture probability publication-title: Osteoporos Int doi: 10.1007/s001980200068 – volume: 15 start-page: 1526 year: 2000 ident: key 2019041114010700100_B4 article-title: Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study publication-title: J Bone Miner Res doi: 10.1359/jbmr.2000.15.8.1526 – volume: 56 start-page: 329 year: 2008 ident: key 2019041114010700100_B12 article-title: Immunolocalization of Periostin-like factor and periostin during embryogenesis publication-title: J Histochem Cytochem doi: 10.1369/jhc.7A7321.2007 – volume: 283 start-page: 17991 year: 2008 ident: key 2019041114010700100_B9 article-title: Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells publication-title: J Biol Chem doi: 10.1074/jbc.M708029200 – volume: 229 start-page: 857 year: 2004 ident: key 2019041114010700100_B14 article-title: Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction publication-title: Dev Dyn doi: 10.1002/dvdy.10453 – volume: 14 start-page: 1239 year: 1999 ident: key 2019041114010700100_B13 article-title: Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta publication-title: J Bone Miner Res doi: 10.1359/jbmr.1999.14.7.1239 – volume: 7 start-page: e31974 year: 2012 ident: key 2019041114010700100_B33 article-title: Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy publication-title: PLoS One doi: 10.1371/journal.pone.0031974 – volume: 109 start-page: 15048 year: 2012 ident: key 2019041114010700100_B17 article-title: Regulation of β catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1203085109 – volume: 23 start-page: 1199 year: 2012 ident: key 2019041114010700100_B10 article-title: The multiple facets of periostin in bone metabolism publication-title: Osteoporos Int doi: 10.1007/s00198-011-1892-7 – volume: 22 start-page: 391 year: 2011 ident: key 2019041114010700100_B3 article-title: Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards publication-title: Osteoporos Int doi: 10.1007/s00198-010-1501-1 – volume: 89 start-page: 4246 year: 2004 ident: key 2019041114010700100_B37 article-title: Aortic calcification and the risk of osteoporosis and fractures publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2003-030964 – volume: 20 start-page: 1813 year: 2005 ident: key 2019041114010700100_B2 article-title: Identification of osteopenic women at high risk of fracture: the OFELY study publication-title: J Bone Miner Res doi: 10.1359/JBMR.050609 – volume: 11 start-page: 337 year: 1996 ident: key 2019041114010700100_B21 article-title: Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis publication-title: J Bone Miner Res doi: 10.1002/jbmr.5650110307 – volume: 27 start-page: 2702 year: 2012 ident: key 2019041114010700100_B32 article-title: Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfr670 – volume: 12 start-page: 683 year: 1997 ident: key 2019041114010700100_B20 article-title: Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort publication-title: J Bone Miner Res doi: 10.1359/jbmr.1997.12.4.683 – volume: 79 start-page: 26 year: 2012 ident: key 2019041114010700100_B7 article-title: Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis publication-title: Joint Bone Spine doi: 10.1016/j.jbspin.2011.05.004 – volume: 25 start-page: 849 year: 2010 ident: key 2019041114010700100_B31 article-title: Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease publication-title: J Bone Miner Res doi: 10.1359/jbmr.090831 – volume: 103 start-page: 183 year: 2001 ident: key 2019041114010700100_B15 article-title: Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation publication-title: Mech Dev doi: 10.1016/S0925-4773(01)00356-2 – volume: 42 start-page: S1 year: 2003 ident: key 2019041114010700100_B22 article-title: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease publication-title: Am J Kidney Dis doi: 10.1016/S0272-6386(03)00905-3 – volume: 8 start-page: 1137 year: 1993 ident: key 2019041114010700100_B23 article-title: Vertebral fracture assessment using a semiquantitative technique publication-title: J Bone Miner Res doi: 10.1002/jbmr.5650080915 |
SSID | ssj0014453 |
Score | 2.3824348 |
Snippet | Purpose:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice... PURPOSE:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice... Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop... |
SourceID | proquest pubmed crossref wolterskluwer oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2533 |
SubjectTerms | Adult Age Aged Aged, 80 and over Bone Density Bone mineral density Bone strength Bone turnover Cell Adhesion Molecules - blood Cohort Studies Collagen (type I) Dual energy X-ray absorptiometry Female Fractures France - epidemiology Hip Humans Middle Aged Osteocalcin Osteoporosis Osteoporotic Fractures - blood Osteoporotic Fractures - epidemiology Periosteum Post-menopause Protein turnover Risk assessment Risk Factors Vertebrae |
Title | Serum Periostin Is Associated With Fracture Risk in Postmenopausal Women: A 7-Year Prospective Analysis of the OFELY Study |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201407000-00030 https://www.ncbi.nlm.nih.gov/pubmed/24628551 https://www.proquest.com/docview/3164458632 https://www.proquest.com/docview/1544321905 |
Volume | 99 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBATQnxTGMhI8FS5SmK7SXgbU8uG-FK1ie4pchLnAbZkaloh9vfxh3FnJ26COmnwEuXDSZTcz7473_3OhLz2uPJAiwRM8zhlIs85i1IZM535qRBhCErNZPl-nhyeiA8LuRgMfneyltardJxdbuWV_I9U4RzIFVmy_yBZ91A4AfsgX9iChGF7LRlDR8c8dnhVBT21HB3V7neDHfkNp1hnyILCIMEcc8ihDa7OixXCL9S6NpPlcGDp6SE7xao-X5dVS7_slSxBC_XLbPrx1OQe9qLBiLVOCQrHttRlXsGoVG7qPJ3rFaDurK1baCI96xq629rAaTw6GLs5H1w7-Rebw0PMxam78k4vcTK3yRdwp5FKgew8o1bm4-58hi9c7uuGX-CzODSLrIOGssNyLCQLfZvJ247bdmGlBp9hdxCWtrZGo9DhMN6qLMDbRWWBhSx9ztBy2yjFNhHgL13pMhjRd4L7k-9ZgncnePcNcjMAZwXVw_uFSzQCj7Wphdp8V0O_QO5U9909w6hHtuz4PLvkzs8K0yjqH4ZF0bGFju-Ru40TQ_ctIu-TgS4fkFufmjSNh-TSAJM6YNKjmm6ASRGYtAUmRWBSaNMHJjXAfEv3qYUl7cCStrCkVUEBltTAkhpYPiIns-nxwSFrFvlgGQfvmSnt5RpsZBUpX0Y-JjH5gS6Epz0ViQLMZVHIAqPJkZJgTsk4CycqwnA6BrlT_pjslFWpnxIqYpWChZtqHoHRmqtI6jQP4zAriizQkRiSUfuHk6ypgI8LsZwl26Q5JG9c6wtb-eWKdhSEdVUTZpvstZJMmt5YJ9wHV0RGEx4MySt3GQZ3jNipUkPvS7BUFgebwpND8sQiwL0oQFY5-DtDwnqQSCyBOjHeP5iiDDsZKHZbQYJ7z675Xc_J7U333CM7q-VavwADfJW-NPj-Ayct1PA |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Periostin+Is+Associated+With+Fracture+Risk+in+Postmenopausal+Women%3A+A+7-Year+Prospective+Analysis+of+the+OFELY+Study&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Rousseau%2C+J.+C.&rft.au=Sornay-Rendu%2C+E.&rft.au=Bertholon%2C+C.&rft.au=Chapurlat%2C+R.&rft.date=2014-07-01&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=99&rft.issue=7&rft.spage=2533&rft.epage=2539&rft_id=info:doi/10.1210%2Fjc.2013-3893&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_jc_2013_3893 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |